The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Should MRD negativity guide treatment de-escalation in high-risk myeloma?
Benjamin Diamond, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses the challenges of treatment de-escalation in patients with high-risk multiple myeloma who achieve measurable residual disease (MRD) negativity. Drawing on findings from the MASTER trial (NCT03224507), Dr Diamond highlights the poorer outcomes observed following treatment de-escalation in patients with high-risk disease despite sustained MRD negativity, emphasizing the need for strategies that maintain deep responses and improve long-term disease control. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
